Four Claims About Peptides That Don't Hold Up — and One That's True
Bottom line
Peptides are having a moment — promoted by influencers, wellness clinics, and even the Secretary of Health and Human Services. But much of what you hear about them doesn't survive contact with the evidence. Drawing on an October 19, 2026 KFF Health News investigation, here are four widely repeated claims about peptides that fall apart under scrutiny — and the one legitimate point buried underneath the hype.
"Peptides aren't drugs"
This one comes from Gary Brecka, a co-chair of the MAHA Action committee, who has said on his Ultimate Human podcast — in an episode recorded at the White House — that peptides aren't drugs, while describing their use to "help regulate cortisol, improve circulation, all kinds of things."
It's wrong as a matter of definition. When a substance is used to treat, prevent, or cure a condition, or to affect the body's structure or function, it is a drug — that's the legal and scientific meaning of the word. "Peptide" just describes a size: chains of amino acids smaller than proteins, built from the same blocks. Humans make many peptides, including insulin — and insulin is unambiguously a drug when people inject it to regulate blood sugar.
As Jacob Sherkow, a University of Illinois law professor specializing in biotechnology, told KFF: most of our drugs had some antecedent in nature. That doesn't make them not drugs.
"Peptides are safe because they're natural"
A common refrain from peptide promoters, repeated by Brecka and by Brigham Buhler — co-author of The Peptide Revolution and owner of a compounding pharmacy and clinic that sell peptides. Some influencers go further, saying peptides are safe because they're made by the human body.
Start with the most popular example, BPC-157. Croatian scientists isolated what they called "body protective compound" from gastric juices in the stomach lining. But researchers have been unable to find a trace of BPC in the human genome — meaning it isn't made by humans, according to Stanford peptide scientist Katrin Svensson. Researchers in Taiwan have suggested it's produced by stomach microbes.
And even genuinely natural substances can be toxic. People have died from taking too much insulin. The only way to learn whether a drug's benefits outweigh its risks — including harms that don't show up immediately, like liver damage — is placebo-controlled trials. That's what the hype is trying to skip.
"These peptides treat illnesses and heal injuries"
Kris Wusterhausen — a new appointee to the FDA's advisory panel on compounding, and founder of an anti-aging company that sells BPC-157 — has said the peptide "can reduce [acid] reflux disease" and treat "neurologic disorders." Similar claims are everywhere: peptides for muscle injuries, COVID, inflammatory bowel disease, and more.
The clinical evidence is vanishingly thin. A summary of a small trial testing BPC-157 for inflammatory bowel disease was published in 2005 but lacked critical details about how it was conducted; FDA scientists who reviewed it called it "inadequate." Another small study found BPC-157 relieved knee pain in 14 of 16 patients — but it had no control group, so the participants might have improved for other reasons. A 2025 review of BPC-157 research for musculoskeletal injuries warned it should be "approached with caution" for lack of evidence.
Laboratory studies get cited as proof — a peptide stimulating blood vessel growth in a dish, for example. That research matters, but it says nothing about safety or efficacy in people, or about off-target effects like fueling cancerous growths. Most substances that look promising in early experiments fail in human trials. As physical rehabilitation doctor Flynn McGuire, a co-author of the 2025 review, put it: he won't prescribe BPC-157 until quality studies exist, because "medicine and science just don't work fast."
"Peptides can't be patented"
Before taking the helm at HHS, Robert F. Kennedy Jr. posted on X that the FDA's "war on public health" included suppressing peptides and other therapies that "can't be patented by Pharma." The idea is all over peptide forums: mainstream medicine sidelined these substances because companies can't patent them and therefore can't profit.
The patent office disagrees. Hundreds of peptide patents are listed in the USPTO database — a patent on an early formulation of BPC-157 is currently for sale. You can't patent the natural substance itself, but modified versions, stable formulations, and delivery methods are all patentable and are being patented, as Sherkow notes. Pharmaceutical companies are actively suing each other over patents on GLP-1 peptides — the basis of Ozempic and similar drugs — in a market Morgan Stanley projects will reach $190 billion within a decade.
So why haven't companies run trials on the popular experimental peptides? Trials cost millions, so a company has to be convinced a drug looks promising enough for FDA approval and has an edge over existing medicines. Some may have looked and been discouraged: Svensson notes companies do early experiments before investing, and USC gerontology scientist Pinchas Cohen told KFF that investors backed out of funding trials on MOTS-c — a peptide he helped discover — because they worried it couldn't compete with GLP-1 drugs.
There's a bitter irony here: the push to make unapproved peptides widely available through compounding could make proper trials less likely, since pharmacies wouldn't need FDA approval to sell them.
The one thing the hype gets right
Kennedy and MAHA-aligned advocates are correct that the US spends more per person on healthcare than any other nation while ranking below all other wealthy nations in life expectancy. They're right about the cost of treatment, too: six in ten US adults say they worry about affording prescription drugs, and four in ten have skipped doses or taken other measures because of the price, according to a recent KFF poll.
But researchers who study how to actually fix those problems point to policies like limiting drug monopolies and improving access to healthy food. Skipping clinical trials to sell unproven treatments isn't on the list.
Frequently asked questions
Are any peptides actually approved medicines?
Yes — many. Insulin, semaglutide (Ozempic/Wegovy), tirzepatide, and others are FDA-approved peptide drugs with real trial data behind them. The problem isn't peptides as a category; it's the experimental, unapproved ones being sold on claims without evidence.
If BPC-157 isn't in the human genome, what is it?
It was isolated from stomach-lining gastric juices by Croatian researchers. Since no trace of it appears in the human genome, researchers believe humans don't produce it — one hypothesis, from researchers in Taiwan, is that it's made by stomach microbes. Either way, "it's natural" was never evidence of safety.
Why would drug companies ignore peptides that work?
They wouldn't — that's the point. Running clinical trials costs millions, so companies test the waters first and invest where the science looks strong enough for approval. When they pass, it's often because the early data didn't convince them, or because the market is already served — as happened with MOTS-c and GLP-1 competition.
Where can I read the original investigation?
KFF Health News published "Four Red Flags and One Truth Amid the Peptide Hype" on October 19, 2026. It's the source for the reporting summarized here and worth reading in full:
This article is educational content, not medical advice. Talk to a qualified clinician about any health decisions. Our editorial standards: https://www.thepeptidesplace.com/editorial-standards
Sources
KFF Health News, Amy Maxmen. "Four Red Flags and One Truth Amid the Peptide Hype." October 19, 2026.
CNN. "People say these peptides hurt them. Their stories are muffled in MAHA's push for medical freedom." October 13, 2026.
Comments